Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 2,700 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 2,700 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $108.87, for a total transaction of $293,949.00. Following the sale, the insider now owns 301,808 shares in the company, valued at approximately $32,857,836.96. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Jonathan Sheena also recently made the following trade(s):

• On Tuesday, June 18th, Jonathan Sheena sold 2,700 shares of Natera stock. The stock was sold at an average price of $109.66, for a total value of $296,082.00.
• On Thursday, May 23rd, Jonathan Sheena sold 1,000 shares of Natera stock. The shares were sold at an average price of $108.30, for a total value of $108,300.00.
• On Thursday, April 25th, Jonathan Sheena sold 1,000 shares of Natera stock. The shares were sold at an average price of $89.55, for a total transaction of $89,550.00.
• On Wednesday, April 3rd, Jonathan Sheena sold 26,700 shares of Natera stock. The stock was sold at an average price of $92.47, for a total transaction of $2,468,949.00.

Natera Stock Up 2.7 %

Shares of NTRA traded up $2.89 during mid-day trading on Tuesday, reaching $110.70. The company had a trading volume of 1,114,651 shares, compared to its average volume of 1,335,518. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $117.23. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.98 and a current ratio of 4.12. The company has a market capitalization of $13.59 billion, a price-to-earnings ratio of -35.48 and a beta of 1.48. The firm has a 50-day moving average price of $105.29 and a 200 day moving average price of $86.70.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.16. The firm had revenue of $367.70 million during the quarter, compared to analyst estimates of $316.31 million. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. Natera’s quarterly revenue was up 52.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.23) EPS. On average, sell-side analysts forecast that Natera, Inc. will post -2.43 EPS for the current year.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its holdings in shares of Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares in the last quarter. YHB Investment Advisors Inc. purchased a new position in shares of Natera during the first quarter valued at approximately $36,000. RiverPark Advisors LLC bought a new position in Natera during the fourth quarter valued at approximately $27,000. Principal Securities Inc. bought a new position in Natera during the fourth quarter valued at approximately $32,000. Finally, Arcadia Investment Management Corp MI boosted its holdings in Natera by 47.8% in the first quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock worth $49,000 after purchasing an additional 174 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the stock. The Goldman Sachs Group upped their price target on shares of Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, April 15th. Piper Sandler raised their price target on Natera from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 14th. BTIG Research boosted their price objective on Natera from $100.00 to $125.00 and gave the company a “buy” rating in a research report on Monday, May 13th. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price on the stock in a research note on Friday, April 5th. Finally, TD Cowen raised their price target on shares of Natera from $123.00 to $137.00 and gave the stock a “buy” rating in a report on Friday, May 10th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $101.19.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.